The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.

The post FDA Approves Zuranolone for the Treatment of Postpartum Depression appeared first on MGH Center for Women’s Mental Health.

Leave a Reply

Your email address will not be published. Required fields are marked *